Liraglutide to Improve corONary Haemodynamics During Exercise streSS
CompletedPhase 2NCT02315001
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
A single-centre double-blind placebo-controlled crossover randomised controlled trial to determine the physiological basis of glucagon-like peptide-1 receptor activation on exercise haemodynamics, as manifest through specific electrophysiological parameters measured by serial exercise stress testing, in those patients with reversible myocardial ischaemia and obstructive coronary artery disease confirmed by a baseline exercise test and coronary angiography respectively.
Study details
- Official title
- The Physiological Effects of GLP-1 on Haemodynamics During Exercise in Patients With Ischaemic Heart Disease
- Conditions
- Ischaemic Heart Disease
- Coronary Heart Disease
- Chronic Stable Angina
- Interventions
- Drug: Liraglutide
- Other: Placebo
- Sponsor
- King's College London
- Collaborators
- Guy's and St Thomas' NHS Foundation Trust
- Start date
- 2014-01
- Primary completion
- 2015-03
- Sex
- All
- Age range
- from 18 Years to 80 Years
- Results posted
- No results posted in this snapshot
- Countries
- United Kingdom
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: 1. Men and women aged 18-80 2. Patients with a recent abnormal exercise tolerance test demonstrating \>0.1 mV of planar or down-sloping ST-segment depression. 3. Patients with known coronary artery disease and angiographic evidence of a \>70% stenosis in a main epicardial artery, with or without coronary stenoses elsewhere. 4. Patients must be able to walk confidently on a treadmill. 5. Patients must have a normal resting electrocardiogram (ECG) in sinus rhythm without bundle branch aberration or other conduction disturbance. 6. Patients must have normal left ventricular function. Exclusion Criteria: 1. An abnormal resting ECG including atrial fibrillation, bundle branch aberration or other conduction disturbance. 2. Pre-existing left ventricular systolic dysfunction. 3. Pre-existing ischaemic or non-ischaemic cardiomyopathy. 4. Pre-existing valvular heart disease. 5. Inability to safely negotiate an exercise treadmill. 6. Type I diabetes mellitus. 7. Type II diabetes mellitus taking oral or subcutaneous anti diabetic therapy.
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT02315001